Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Colorcon
Dow
Johnson and Johnson
Boehringer Ingelheim

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR ADRUCIL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Adrucil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed M.D. Anderson Cancer Center Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002525 ↗ Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed Terminated American College of Surgeons Phase 3 1993-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Adrucil

Condition Name

Condition Name for Adrucil
Intervention Trials
Breast Cancer 8
Esophageal Cancer 5
Colorectal Cancer 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Adrucil
Intervention Trials
Adenocarcinoma 17
Colorectal Neoplasms 14
Pancreatic Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Adrucil

Trials by Country

Trials by Country for Adrucil
Location Trials
United States 326
Spain 29
Japan 18
Belgium 14
Australia 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Adrucil
Location Trials
Texas 33
California 19
Michigan 14
Illinois 14
Pennsylvania 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Adrucil

Clinical Trial Phase

Clinical Trial Phase for Adrucil
Clinical Trial Phase Trials
Phase 3 8
Phase 2/Phase 3 3
Phase 2 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Adrucil
Clinical Trial Phase Trials
Completed 36
Recruiting 12
Terminated 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Adrucil

Sponsor Name

Sponsor Name for Adrucil
Sponsor Trials
National Cancer Institute (NCI) 30
M.D. Anderson Cancer Center 25
Genentech, Inc. 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Adrucil
Sponsor Trials
Other 71
Industry 46
NIH 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Baxter
Johnson and Johnson
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.